These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
681 related articles for article (PubMed ID: 26316560)
1. Skin and soft-tissue infections: a critical review and the role of telavancin in their treatment. Cardona AF; Wilson SE Clin Infect Dis; 2015 Sep; 61 Suppl 2():S69-78. PubMed ID: 26316560 [TBL] [Abstract][Full Text] [Related]
2. Review of meta-analyses of vancomycin compared with new treatments for Gram-positive skin and soft-tissue infections: Are we any clearer? Tsoulas C; Nathwani D Int J Antimicrob Agents; 2015 Jul; 46(1):1-7. PubMed ID: 25982913 [TBL] [Abstract][Full Text] [Related]
3. Hospitalist perspective on the treatment of skin and soft tissue infections. Amin AN; Cerceo EA; Deitelzweig SB; Pile JC; Rosenberg DJ; Sherman BM Mayo Clin Proc; 2014 Oct; 89(10):1436-51. PubMed ID: 24974260 [TBL] [Abstract][Full Text] [Related]
4. The importance of tissue penetration in achieving successful antimicrobial treatment of nosocomial pneumonia and complicated skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus: vancomycin and linezolid. Stein GE; Wells EM Curr Med Res Opin; 2010 Mar; 26(3):571-88. PubMed ID: 20055750 [TBL] [Abstract][Full Text] [Related]
5. Emerging issues in the diagnosis and management of infections caused by multi-drug-resistant, gram-positive cocci. Napolitano LM Surg Infect (Larchmt); 2005; 6 Suppl 2():S-5-22. PubMed ID: 23577494 [TBL] [Abstract][Full Text] [Related]
6. Treatments for skin and soft-tissue and surgical site infections due to MDR Gram-positive bacteria. Stevens DL J Infect; 2009 Sep; 59 Suppl 1():S32-9. PubMed ID: 19766887 [TBL] [Abstract][Full Text] [Related]
7. Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria. Stryjewski ME; O'Riordan WD; Lau WK; Pien FD; Dunbar LM; Vallee M; Fowler VG; Chu VH; Spencer E; Barriere SL; Kitt MM; Cabell CH; Corey GR; Clin Infect Dis; 2005 Jun; 40(11):1601-7. PubMed ID: 15889357 [TBL] [Abstract][Full Text] [Related]
9. Treatment of infections due to resistant Staphylococcus aureus. Anstead GM; Cadena J; Javeri H Methods Mol Biol; 2014; 1085():259-309. PubMed ID: 24085702 [TBL] [Abstract][Full Text] [Related]
10. Contemporary causes of skin and soft tissue infections in North America, Latin America, and Europe: report from the SENTRY Antimicrobial Surveillance Program (1998-2004). Moet GJ; Jones RN; Biedenbach DJ; Stilwell MG; Fritsche TR Diagn Microbiol Infect Dis; 2007 Jan; 57(1):7-13. PubMed ID: 17059876 [TBL] [Abstract][Full Text] [Related]
11. Telavancin: mechanisms of action, in vitro activity, and mechanisms of resistance. Karlowsky JA; Nichol K; Zhanel GG Clin Infect Dis; 2015 Sep; 61 Suppl 2():S58-68. PubMed ID: 26316559 [TBL] [Abstract][Full Text] [Related]
12. The times they are a-changin': new antibacterials for skin and skin structure infections. Tran MC; Naumovski S; Goldstein EJ Am J Clin Dermatol; 2015 Jun; 16(3):137-46. PubMed ID: 25906205 [TBL] [Abstract][Full Text] [Related]
14. Acute bacterial skin infections: developments since the 2005 Infectious Diseases Society of America (IDSA) guidelines. Moran GJ; Abrahamian FM; Lovecchio F; Talan DA J Emerg Med; 2013 Jun; 44(6):e397-412. PubMed ID: 23466022 [TBL] [Abstract][Full Text] [Related]
15. New antibiotics in the management of acute bacterial skin and skin structure infections. Gleghorn K; Grimshaw E; Kelly EK Skin Therapy Lett; 2015; 20(5):7-9. PubMed ID: 26382907 [TBL] [Abstract][Full Text] [Related]
16. Treatment of infections caused by resistant Staphylococcus aureus. Anstead GM; Quinones-Nazario G; Lewis JS Methods Mol Biol; 2007; 391():227-58. PubMed ID: 18025681 [TBL] [Abstract][Full Text] [Related]
17. Newer treatment options for skin and soft tissue infections. Raghavan M; Linden PK Drugs; 2004; 64(15):1621-42. PubMed ID: 15257625 [TBL] [Abstract][Full Text] [Related]
18. [Role of daptomycin in the empirical and directed therapy of infections caused by Gram-positive bacteria in the critically ill patient]. Garnacho-Montero J; Amaya-Villar R; Gómez-Grande ML; Jerez V; Lorente-Ramos L; Loza A; Martínez A; Pozo JC; Sierra R; Pomares J; de la Torre MV; Ortiz C Rev Esp Quimioter; 2011 Mar; 24(1):13-24. PubMed ID: 21412665 [TBL] [Abstract][Full Text] [Related]
19. Obesity and skin and soft tissue infections: how to optimize antimicrobial usage for prevention and treatment? Grupper M; Nicolau DP Curr Opin Infect Dis; 2017 Apr; 30(2):180-191. PubMed ID: 28118218 [TBL] [Abstract][Full Text] [Related]
20. The role of telavancin in hospital-acquired pneumonia and ventilator-associated pneumonia. Sandrock CE; Shorr AF Clin Infect Dis; 2015 Sep; 61 Suppl 2():S79-86. PubMed ID: 26316561 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]